BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
BioAge Labs, Inc.NASDAQ: BIOA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns positive
Q1 FY2026 financing cash flow was $123.72M, compared with -$1.5M a year earlier. Trailing-twelve-month financing cash flow was $136.68M. Over 3 fiscal years it compounded at +66.2% a year.
Context
- Financing cash flow amounted to 127.5% of revenue in FY2025.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $123.72M or moves back toward the trailing-twelve-month quarterly average of $34.17M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 11.47M USD
- Year-over-year change
- -97.0%
- 3-year CAGR
- +66.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.47M | -97.0% |
| FY2024 | 2024-12-31 | 381.2M | +991.0% |
| FY2023 | 2023-12-31 | 34.94M | +1298.2% |
| FY2022 | 2022-12-31 | 2.5M | — |
Financing Cash Flow vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -35.4% is the 6th highest of 9, against a peer median of +61.8%.
- Financing cash flow amounts to 1325.0% of revenue for BIOA, versus a peer median of 56.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$366.4M CAD | +146.5% | — | 117.3% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $136.68M USD | -35.4% | +66.2% | 1325.0% |
| LTM Mar 2026 | $126.17M USD | +2854.7% | +44.9% | — | |
| LTM Mar 2026 | $41.91M USD | -23.0% | +215.9% | 108.3% | |
| LTM Mar 2026 | $38.07M USD | -61.2% | — | 1888.3% | |
| LTM Mar 2026 | $37.29M USD | -71.1% | +117.0% | — | |
| LTM Mar 2026 | $25.14M USD | +10830.9% | — | — | |
| LTM Mar 2026 | CA$9.8M CAD | +1152.7% | — | 3.2% | |
| LTM Mar 2026 | $5.09M USD | — | — | 3.8% | |
| LTM Mar 2026 | $85K USD | -100.6% | -75.5% | 0.2% | |
| Peer median (excluding BIOA) | — | +61.8% | +81.0% | 56.0% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.